NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced that Thomas T. Higgins, Senior Vice President and Chief Financial Officer, is scheduled to speak at the Rodman & Renshaw Annual Global Investment Conference at The Waldorf Astoria, New York, NY on September 9-11, 2012. Mr. Higgins intends to provide an update on the Company’s business activities and on its diabetes products including NC-stat ® DPNCheck ™, a diagnostic test for systemic neuropathies such as diabetic peripheral neuropathy (DPN), and the SENSUS ™ pain management device for relief of chronic intractable pain.
NeuroMetrix's presentation is scheduled for Tuesday, September 11, 2012 at 4:30 PM (Eastern Daylight Time) in the North Foyer. A live audio webcast will be available on the investor relations section of the corporate website - www.neurometrix.com. This webcast will be archived after the live event.
NeuroMetrix is an innovative medical device company that develops and markets home use and point-of-care devices, associated consumables, and support software for the treatment and management of diabetes and its complications. The company is focused on nerve related complications of diabetes, called diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation, cause disabling chronic pain, and increase the risk of falling in the elderly. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company’s products are used by physicians and other clinicians, in retail health settings such as pharmacies, and by managed care organizations to optimize patient care and reduce healthcare costs. The company markets the NC-stat ® DPNCheck ™ device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. The company is in late stage development of SENSUS ™, a pain management device which recently received Food and Drug Administration clearance. The company has additional therapeutic products in its pipeline. For more information, please visit http://www.neurometrix.com.